Panacea Biotec Q2 Results FY27: Profit Swings Against Last Year’s Loss, Revenue Rs 189.67 Cr, PAT Rs 11.91 Cr
- November 14, 2026
- Posted by: Harsh Piplani
- Category: Results
Quick Answer
Panacea Biotec Q2 Results FY27 were declared on 14 November 2026 on a consolidated basis. The quarterly results show revenue of Rs 189.67 Cr, up 34.39% YoY from Rs 141.13 Cr, and net profit of Rs 11.91 Cr against a loss of Rs 14.01 Cr a year earlier. Operating Profit came in at Rs 15.5 Cr versus a loss of Rs 17.79 Cr, so YoY growth is visible across all three lines.
Panacea Biotec Ltd (PANACEABIO) Q2 Results FY27 announced on 14 November 2026, covering the company’s financial performance for the July to September quarter. Consolidated revenue came in at Rs 189.67 Cr and net profit at Rs 11.91 Cr. Panacea Biotec Q2 Results FY27 sit on a consolidated results basis, and the results date places the numbers beside the Rs 141.13 Cr revenue and Rs 14.01 Cr loss of the same quarter last year.
This Panacea Biotec Q2 Results analysis covers the financial highlights, the business drivers, the FY27 outlook and the risks that follow the filing. The results analysis below uses only the figures disclosed for the quarter on NSE and BSE, and it begins with the Financial Highlights table.
Click Here – Get Free Investment Predictions
Panacea Biotec Q2 Results FY27: Financial Highlights
| Metric | Q2 FY27 (Sep 26) | Q2 FY26 (Sep 25) | YoY Change |
|---|---|---|---|
| Revenue | Rs 189.67 Cr | Rs 141.13 Cr | +34.39% YoY |
| Operating Profit | Rs 15.5 Cr | Rs -17.79 Cr | +187.13% YoY |
| Net Profit (PAT) | Rs 11.91 Cr | Rs -14.01 Cr | +185.01% YoY |
Source: company filing for Panacea Biotec Q2 Results FY27, 14 November 2026. Figures in Rs Crore, Consolidated basis.
Key Takeaways from Panacea Biotec Q2 Results: What Stands Out
- Revenue rose 34.39% YoY to Rs 189.67 Cr from Rs 141.13 Cr, which is the clearest sign of YoY growth in this consolidated update.
- Net profit of Rs 11.91 Cr compares with a loss of Rs 14.01 Cr a year earlier, a 185.01% YoY change on the supplied figures.
- Operating Profit reached Rs 15.5 Cr against a loss of Rs 17.79 Cr in the comparison quarter, a 187.13% YoY change.
- Net profit margin improved to 6.3% from -9.9% in the comparison quarter, based on the disclosed revenue and profit figures.
- Panacea Biotec Q2 Results FY27 also sit beside a debt-to-assets ratio of 0.03 for FY26, and the performance analysis now places these points in context.
Panacea Biotec Q2 Results FY27: Performance Analysis
The results analysis shows consolidated revenue of Rs 189.67 Cr, up 34.39% YoY from Rs 141.13 Cr, with net profit at Rs 11.91 Cr against a loss of Rs 14.01 Cr. Operating Profit moved from a loss of Rs 17.79 Cr to a profit of Rs 15.5 Cr over the same comparison.
Panacea Biotec Q2 Results FY27 therefore describe a quarter in which every reported line moved in the same direction. Revenue added Rs 48.54 Cr over the year-ago figure, net profit improved by Rs 25.92 Cr and Operating Profit improved by Rs 33.29 Cr, all simple differences of the supplied numbers.
Readers of the quarterly results will want to see whether consolidated revenue stays near this level in later filings. Because Panacea Biotec Q2 Results cover a single quarter, the YoY growth seen here is best read beside the next disclosure, which is where the results analysis turns to the business factors.
Check the Univest Screener for live results data
Key Business Factors This Quarter
Revenue Growth – The results analysis points first to revenue, which grew 34.4% year on year to Rs 189.67 Cr in the latest quarter. That growth is the base on which the Operating Profit and net profit lines for the quarter were built.
Return to Net Profit – The company returned to a net profit of Rs 11.91 Cr from a loss in the comparison quarter. Panacea Biotec Q2 Results FY27 record this move on a consolidated basis, which makes it the most visible change in the filing.
Net Profit Margin – Net profit margin improved to 6.3% from -9.9% in the comparison quarter. The company is also almost debt free, with a debt-to-assets ratio of 0.03 in FY26, which the quarterly results sit beside.
FY27 Outlook After Panacea Biotec Q2 Results
The full-year picture for FY27 will depend on the quarters that follow and on the conditions disclosed alongside them. This quarter gives one data point of Rs 189.67 Cr in revenue and Rs 11.91 Cr in net profit, and a results analysis for the year needs more filings than one.
Panacea Biotec Q2 Results FY27 do not carry management guidance, so no forward number is drawn from them. Investors can follow the next consolidated filing and compare its net profit with Rs 11.91 Cr, which is where the outlook hands over to the risks.
Key Risks to Watch After Panacea Biotec Q2 Results FY27
Low Return on Equity
Return on equity was low at -0.86% in FY26. Investors reading Panacea Biotec Q2 Results FY27 may weigh this full-year figure against the single-quarter profit, since one quarter does not yet change the annual picture.
Modest Return on Capital Employed
Return on capital employed was modest at -0.15% in FY26. This annual figure remains below zero, so the quarter’s YoY growth in profit sits beside a capital return that is still to be tracked in later filings.
Volatile Quarterly Net Profit
Quarterly net profit has been volatile, ranging from Rs -14.01 Cr to Rs 11.91 Cr over the last 5 quarters. A swing of this size means one filing should not be read as a settled trend.
Download the Univest iOS App or Univest Android App to track quarterly results as they are declared.
Conclusion
Panacea Biotec Q2 Results FY27 show consolidated revenue of Rs 189.67 Cr, net profit of Rs 11.91 Cr and Operating Profit of Rs 15.5 Cr. The quarterly results and the consolidated results basis give a clear YoY picture for the quarter, and the Panacea Biotec Q2 Results should be read with later filings. Investors should consult a SEBI-registered advisor before acting.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.
Frequently Asked Questions on Panacea Biotec Q2 Results FY27
What are Panacea Biotec Q2 Results FY27?
Ans. Panacea Biotec Q2 Results FY27 cover the July to September 2026 quarter on a consolidated basis, with revenue of Rs 189.67 Cr and net profit of Rs 11.91 Cr, as summarised in the Quick Answer section.
What is the results date for Panacea Biotec Q2 Results FY27?
Ans. Panacea Biotec declared the quarter’s figures on 14 November 2026, so the results date is 14 November 2026, which is also the date used in the Quick Answer at the top of this article.
What revenue was reported in Panacea Biotec Q2 Results FY27?
Ans. Panacea Biotec Q2 Results FY27 report revenue of Rs 189.67 Cr, compared with Rs 141.13 Cr a year earlier, so the Financial Highlights table shows the comparison quarter figure beside it.
What net profit was reported in Panacea Biotec Q2 Results FY27?
Ans. Panacea Biotec reported a net profit of Rs 11.91 Cr, while the same quarter last year showed a loss of Rs 14.01 Cr, as the Key Takeaways section explains.
How much YoY growth did revenue show in Panacea Biotec Q2 Results FY27?
Ans. Revenue shows YoY growth of 34.39%, which means the quarter added Rs 48.54 Cr over the year-ago figure, and the Performance Analysis section covers this difference in more detail.
Did net profit rise or fall in Panacea Biotec Q2 Results?
Ans. Net profit rose in Panacea Biotec Q2 Results, moving from a loss of Rs 14.01 Cr to a profit of Rs 11.91 Cr, which is a 185.01% YoY change as the Key Takeaways section notes.
What was the Operating Profit in Panacea Biotec Q2 Results FY27?
Ans. Operating Profit was Rs 15.5 Cr, compared with a loss of Rs 17.79 Cr a year earlier, a 187.13% YoY change that the Performance Analysis section places beside revenue.
Are Panacea Biotec Q2 Results consolidated results or standalone results?
Ans. Panacea Biotec Q2 Results are consolidated results, so the revenue of Rs 189.67 Cr and net profit of Rs 11.91 Cr reflect the consolidated basis, as the opening paragraphs of this article state.
What business factors shaped Panacea Biotec Q2 Results FY27?
Ans. Revenue growth of 34.4% year on year, the return to a net profit of Rs 11.91 Cr and a margin of 6.3% shaped the quarter, as the Key Business Factors section explains.
What are the key risks after Panacea Biotec Q2 Results FY27?
Ans. Return on equity of -0.86%, return on capital employed of -0.15% and volatile quarterly net profit are the risks listed, and the Key Risks section covers each of them in turn.
What is the outlook after Panacea Biotec Q2 Results?
Ans. The FY27 outlook depends on later quarters, because Panacea Biotec Q2 Results give one data point of Rs 189.67 Cr in revenue, and the Outlook section explains why no guidance is drawn from it.
Where can I find the complete Panacea Biotec Q2 Results FY27 data?
Ans. The full Panacea Biotec filing is available on NSE and BSE, while the Financial Highlights table above and the Univest Screener show the same consolidated revenue and net profit figures.
